After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Portfolio Pulse from Vandana Singh
Sage Therapeutics' dalzanemdor failed to show significant results in a Phase 2 Alzheimer's study, leading to the discontinuation of its development for this condition. The company's stock dropped 11.30% following the news. Biogen had previously terminated its collaboration with Sage on a different program.
October 08, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen had previously terminated its collaboration with Sage Therapeutics on the SAGE-324 program. This decision was made before the recent negative results of Sage's Alzheimer's study.
Biogen's earlier decision to terminate its collaboration with Sage on the SAGE-324 program is indirectly related to the current news. While it does not directly impact Biogen's stock, it highlights Biogen's strategic decision-making in its partnerships.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
Sage Therapeutics' dalzanemdor failed to show significant results in a Phase 2 Alzheimer's study, leading to the discontinuation of its development for this condition. The company's stock dropped 11.30% following the news.
The failure of the Alzheimer's study is a significant setback for Sage Therapeutics, as it leads to the discontinuation of dalzanemdor's development for this condition. This negative outcome, combined with previous failures in Parkinson's and Huntington's studies, has likely contributed to the 11.30% drop in SAGE's stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100